OPGx-NR2E3
Enhanced S-Cone Syndrome / Retinitis Pigmentosa (NR2E3)
PreclinicalActive
Key Facts
Indication
Enhanced S-Cone Syndrome / Retinitis Pigmentosa (NR2E3)
Phase
Preclinical
Status
Active
Company
About Opus Genetics
Opus Genetics is on a mission to develop and deliver transformative gene therapies for patients with inherited retinal diseases, a leading cause of blindness. The company has advanced its lead candidate, OPGx-LCA5, into a Phase 1/2 clinical trial for LCA5-mediated Leber congenital amaurosis, built upon a platform validated by foundational research from UPenn. Its strategy employs a focused subsidiary model to drive program-specific agility and is supported by public market funding. Opus aims to address high-unmet-need, monogenic retinal conditions with a targeted pipeline designed to demonstrate proof-of-concept and expand into broader indications.
View full company profile